Compounds > vitamin-k-semiquinone-radical

vitamin-k-semiquinone-radical and Anemia--Refractory

vitamin-k-semiquinone-radical has been researched along with Anemia--Refractory* in 1 studies

Other Studies

1 other study(ies) available for vitamin-k-semiquinone-radical and Anemia--Refractory

Article	Year
Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. International journal of hematology, 1999, Volume: 69, Issue:1 Although vitamin K2 is an inducer of the in vitro differentiation of myeloid leukemic cell lines, its clinical efficacy in the treatment of myelodysplastic syndrome (MDS) is unclear. We administered a vitamin K2 analog, menatetrenone, at 45 mg daily to an 80-year-old woman with MDS (refractory anemia) heavily dependent on red-cell transfusions. The patient's pancytopenia gradually improved, and she became transfusion-independent after 14 months. Pancytopenia recurred when menatetrenone was discontinued but recovered again with readministration. Administration of menatetrenone at a dose effective in improving osteoporosis may also be useful in restoring hematopoiesis in MDS patients, possibly by way of inducing differentiation. Topics: Aged; Aged, 80 and over; Anemia, Refractory; Apoptosis; Calcifediol; Cell Differentiation; Drug Therapy, Combination; Female; Humans; Osteoporosis, Postmenopausal; Vitamin K; Vitamin K 2	1999

Article

Year

Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog.

International journal of hematology, 1999, Volume: 69, Issue:1

Although vitamin K2 is an inducer of the in vitro differentiation of myeloid leukemic cell lines, its clinical efficacy in the treatment of myelodysplastic syndrome (MDS) is unclear. We administered a vitamin K2 analog, menatetrenone, at 45 mg daily to an 80-year-old woman with MDS (refractory anemia) heavily dependent on red-cell transfusions. The patient's pancytopenia gradually improved, and she became transfusion-independent after 14 months. Pancytopenia recurred when menatetrenone was discontinued but recovered again with readministration. Administration of menatetrenone at a dose effective in improving osteoporosis may also be useful in restoring hematopoiesis in MDS patients, possibly by way of inducing differentiation.

Topics: Aged; Aged, 80 and over; Anemia, Refractory; Apoptosis; Calcifediol; Cell Differentiation; Drug Therapy, Combination; Female; Humans; Osteoporosis, Postmenopausal; Vitamin K; Vitamin K 2

1999